Allergan closes $125m Oculeve buy
Allergan said yesterday it closed its purchase of dry eye disease device developer Oculeve for $125 million in up-front payments in addition to unspecified commercialization milestones. South San Francisco-based Oculeve is developing a product called OD-01, a non-invasive nasal neurostimulation device designed to increase tear production in patients with dry eye disease, Allergan said. Oculeve has completed 4 clinical trials of OD-01 to date. “The acquisition of Oculeve further enhances Allergan’s world-class position in eye care and underscores our commitment to continuing to develop a broad range of treatment options for patients with eye conditions. Dry eye is currently an underserved condition, with many patients not receiving adequate treatment from over-the-counter options. Allergan is committed to expanding our product offerings in this category, and the development of OD-01, an intranasal neurostimulation device, is complementary to our market-leading dry eye treatment, Restasis, as well as other dry eye products in development within our pipeline,” Allergan CEO Brent Saunders said in a press release. A pair of pivotal trials ahead of submission for FDA approval, expected next year, with commercialization potentially following in 2017, according to Dublin-based Allergan. Allergan announced the deal last week, and reinforced its prior 2015 earnings-per-share guidance for $17 to $18 is unchanged as a result of the acquisit...
Conditions: Keratoconus; Dry Eye; Allergy Intervention: Drug: dexamethasone ophthalmic insert 0.4 mg, for intracanalicular use Sponsor: Illinois College of Optometry Not yet recruiting
Mid Valley Pharmaceutical is recalling lot# 23221701 of Doctor Manzanilla Cough&Cold and lot# 23221701 of Doctor Manzanilla Allergy&Decongestant Relief syrup to the consumer level. The products may potentially be contaminated with the bacteria Burkholderia cepacia. Contaminated products with Burkholderia cepacia can potentially result in serious infections, may be life-threating in patients with compromised immune systems. To date, Mid Valley Pharmaceutical, LLC has not received any reports of adverse events related to this recall.
Drs Andrew Wilner and William Li discuss recent findings suggesting that many of the symptoms of SARS-CoV-2 -- stroke included -- may be due to underlying vascular pathology.Medscape Neurology
Conclusions: This real-world study confirms the high frequency of FGIDs in infants in France, and provides new information regarding the characteristics of FGID infants.
Molecules, Vol. 25, Pages 2622: Generation of High Affinity Anti-Peptide Polyclonal Antibodies Recognizing Goat αs1-Casein Molecules doi: 10.3390/molecules25112622 Authors: Aliah Zannierah Mohsin Rashidah Sukor Jinap Selamat Anis Shobirin Meor Hussin Intan Hakimah Ismail Nuzul Noorahya Jambari Farina Mustaffa-Kamal The chemical, technological and allergy properties of goat’s milk are significantly affected by the level of αs1-casein. Detection and quantification of αs1-casein requires high-specificity methods to overcome high-sequence similarity between this protein a...
Conclusions: Keeping a dog at home before and during pregnancy decreased the risk of food allergy in 1-year-old children. This effect was eliminated in case of having a cat, hamster, guinea pig, or rabbit. PMID: 32489363 [PubMed]
A review of FDA reports also shows notably higher rates of shingles in women among younger patients taking disease-modifying therapies for multiple sclerosis.Medscape Medical News
WebMD Chief Medical Officer John Whyte talks with Dr Deepak Bhatt about the ways COVID-19 puts heart disease patients at risk and also causes new heart problems.WebMD
Condition: Peanut Allergy Interventions: Dietary Supplement: High dose of peanuts; Dietary Supplement: Low dose of peanuts Sponsor: Medical University of Warsaw Not yet recruiting
Condition: Temple Hollowing Intervention: Device: JUVÉDERM VOLUMA® XC Sponsor: Allergan Recruiting